The EDGE in biospecimens
End-to-end biospecimen procurement built by scientists who've run the full value chain, from collection through characterization to delivery. Longitudinal by design, functionally characterized, audit-ready, and the on-ramp to everything else Aqtual does.
Sourced and characterized by the same team.
Most biospecimen programs hand you samples and stop. Aqtual runs the full value chain in-house: the scientists who source your cohort also characterize it on our active-chromatin platform. So samples don't just arrive collected; they arrive functionally characterized against the same ontology we use across every Aqtual program.
Build a cohort, get a timeline, request a quote.
Tell us what you need; we'll show you a realistic timeline and route your request to our team the same business day.
Start with the disease, not the sample.
Every estimate is built from the accrual rate of real sites in that indication. Picking specific disease states sharpens the timeline and lets us match annotation to what your protocol actually needs.
- 150+ disease states across 250+ partnered sites
- Healthy and matched controls available in any area
- Rheumatology / Autoimmune
- Rheumatoid arthritis
- Plasma · double-spun K2-EDTA
- Prospective collection
- 100
- Quarterly
- Samples + cfDNAac
What you get.
Novel signal access
Longitudinal collection
Functional-state ontology
One cohort, many ways forward.
Because everything connects, a single EDGE engagement can extend across Aqtual's offering, with no re-sourcing, re-consenting, or re-collecting. The cohort you design here is the raw material the rest of the platform builds on.
Start with the cohort.
Design a cohort and get a same-business-day response, then take it as far into the platform as your program needs.